Paul Tudor Jones's NKTR Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 14,984 shares of Nektar Therapeutics (NKTR) worth $1.08 M, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in NKTR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 14,984 shares. Largest reduction occurred in Q4 2025, reducing 5,435 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Nektar Therapeutics (NKTR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nektar Therapeutics (NKTR) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +14,984 | New Buy | 14,984 | $71.95 |
| Q4 2025 | -5,435 | Sold Out | 0 | $0.00 |
| Q3 2025 | +5,435 | New Buy | 5,435 | $56.90 |
Paul Tudor Jones's Nektar Therapeutics Investment FAQs
Paul Tudor Jones first purchased Nektar Therapeutics (NKTR) in Q3 2025, acquiring 5,435 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Nektar Therapeutics (NKTR) for 3 quarters since Q3 2025.
Paul Tudor Jones's largest addition to Nektar Therapeutics (NKTR) was in Q1 2026, adding 14,984 shares worth $1.08 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 14,984 shares of Nektar Therapeutics (NKTR), valued at approximately $1.08 M.
As of the Q1 2026 filing, Nektar Therapeutics (NKTR) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Nektar Therapeutics (NKTR) was 14,984 shares, as reported at the end of Q1 2026.